Accessibility settings

This paper is in the following e-collection/theme issue:

RCTs - Protocols/Proposals (non-eHealth) (454) Methods and Feasibility Studies (553) Pharmacology and Pharmaceutics (128) Immunology, Allergy, Rheumatology (156) Chronic Conditions (491)

Published on in Vol 15 (2026)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/87156, first published .
Tripterygium Glycoside Tablets Combined With Conventional Synthetic Disease-Modifying Antirheumatic Drugs for Treating Rheumatoid Arthritis: Protocol for a Prospective, Multicenter, Open-Label Randomized Controlled Trial

Tripterygium Glycoside Tablets Combined With Conventional Synthetic Disease-Modifying Antirheumatic Drugs for Treating Rheumatoid Arthritis: Protocol for a Prospective, Multicenter, Open-Label Randomized Controlled Trial

Tripterygium Glycoside Tablets Combined With Conventional Synthetic Disease-Modifying Antirheumatic Drugs for Treating Rheumatoid Arthritis: Protocol for a Prospective, Multicenter, Open-Label Randomized Controlled Trial

Authors of this article:

Liu Lv1 Author Orcid Image ;   Tuoran Wang2 Author Orcid Image ;   Jing Lv3 Author Orcid Image ;   Chunping Liu1 Author Orcid Image ;   Luming Zhao1 Author Orcid Image ;   Yu Zhou2 Author Orcid Image
Article Authors Cited by Tweetations Metrics
All Time | Last Month | Last Six Months | Last Year
There are currently no tweets available for this article within the specified range.